Drug Trial Radar · NCT06635824
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
191
Actual
Start
Nov 25, 2024
Primary completion
Jul 30, 2027
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the locally advanced (unresectable stage IIIB/C) or metastatic setting.
Conditions
- PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Interventions
AcasunlimabDrug
IV infusion
PembrolizumabDrug
IV infusion
DocetaxelDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 5 years
Locations
247 sites in 27 countries. Site status is shown where the registry gives one.
Arizona Blood and Cancer Specialists
Tucson, Arizona
Usc Norris Comprehensive Cancer Center
Los Angeles, California
Kaiser Permanente Vallejo Medical Center
Vallejo, California
Ocala Oncology Center P.L.
Ocala, Florida
Orlando Regional Medical Center
Orlando, Florida
University Cancer & Blood Center, LLC
Athens, Georgia
Piedmont Cancer Institute Atlanta
Atlanta, Georgia
Piedmont Cancer Institute - Sandy Springs (Atlanta) Office
Atlanta, Georgia
Piedmont Cancer Institute - Fayetteville Office
Fayetteville, Georgia
Piedmont Cancer Institute - Newnan Office
Newnan, Georgia
Piedmont Cancer Institute - Stockbridge Office
Stockbridge, Georgia
Kaiser Foundation Hospitals
Honolulu, Hawaii
University of Illinois
Chicago, Illinois
Community Cancer Center East Medical Oncology Hematology
Indianapolis, Indiana
Baptist Health Lexington
Lexington, Kentucky
Norton Cancer Institute
Louisville, Kentucky
Pikeville Medical Center
Pikeville, Kentucky
Washington University School of Medicine
St Louis, Missouri
St. Francis Hospital - Grand Island
Grand Island, Nebraska
Oncology Hematology West
Omaha, Nebraska
Oncology Hematology West, PC dba Nebraska Cancer Specialists
Omaha, Nebraska
Stony Brook University Medical Center|University Medical Center
Stony Brook, New York
Novant Health Pharmacy
Charlotte, North Carolina
Novant Health Oncology Specialists
Winston-Salem, North Carolina
University of Pennsylvania Health System
Philadelphia, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania
Avera Cancer Institute
Sioux Falls, South Dakota
Parkridge Medical Center
Chattanooga, Tennessee
University of Tennessee Medical Center Cancer Institute
Knoxville, Tennessee
Midtown Tennessee Oncology
Nashville, Tennessee
Tennessee Oncology
Nashville, Tennessee
Texas Oncology-Austin Midtown
Austin, Texas
Texas Oncology-Austin Central
Austin, Texas
South Austin Cancer Ctr
Austin, Texas
University of Virginia Hematology and Oncology
Charlottesville, Virginia
Cancer Institute At Swedish Med Ctr
Seattle, Washington
Hospital Italiano de Buenos Aires
Ciudad Autonoma Buenos Aires, Argentina
Investigaciones CORI S.R.L.
La Rioja, Argentina
Hospital Italiano de La Plata
La Plata, Buenos Aires, Argentina
Centro de Investigacion Pergamino S.A.
Pergamino, Buenos Aires, Argentina
Showing 40 of 247 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.